Nanonization of new patent protected substances - carrier selection for preclinical research: physicochemical and in vivo behavioral characterization

dc.creator	Mitrović, Jelena
dc.creator	Divović, Branka
dc.creator	Dobričić, Vladimir
dc.creator	Čalija, Bojan
dc.creator	Vulić, Jelena P.
dc.creator	Knutson, Daniel E.
dc.creator	Cook, James M.
dc.creator	Savić, Miroslav
dc.creator	Savić, Snežana
dc.date.accessioned	2024-02-19T14:02:09Z
dc.date.available	2024-02-19T14:02:09Z
dc.date.issued	2019
dc.identifier.uri	https://farfar.pharmacy.bg.ac.rs/handle/123456789/5542
dc.description.abstract	Deuterated pyrazoloquinolinones, GABAn receptor ligands, are being investigated for neuropsychiatric disorders treatment. Among others, DK-l-56-1 (7-Methoxy-2-(4-methoxy-d3- p h e n yl ) - 2, 5 -d i h yd ro - 3 H - py r azolo -14,3 -clq u i n o I i n - 3-one) was chosen as the lead component [1]. Because of its low solubility in water (6.27 t0.74 pg/ml) nanosuspension formulation for prospective parenteral administration was carried out [2]. ...	sr
dc.language.iso	en	sr
dc.rights	restrictedAccess	sr
dc.source	10th International Congress Nanotechnology in Medicine & Biology, 15 - 17. April 2019, Graz / Austria	sr
dc.title	Nanonization of new patent protected substances - carrier selection for preclinical research: physicochemical and in vivo behavioral characterization	sr
dc.type	conferenceObject	sr
dc.rights.license	ARR	sr
dc.description.other	BioNanoMed 2019	sr
dc.identifier.rcub	https://hdl.handle.net/21.15107/rcub_farfar_5542
dc.type.version	publishedVersion	sr